17 Aug

Clinical trial continuity in NZ: Optimal Clinical Trials

Extracted from Optimal Clinical Trials EDM – 17th August 2020. Published with permission.

  • New Zealand has been COVID-19 free for 102 days but there are now new community transmitted cases
  • Auckland is in Alert level 3 from Wed 12 Aug until 11:59pm Wed 26 Aug
  • Rest of New Zealand is at Alert level 2
  • Fast response from government
  • Clinical Trials are considered an essential business in New Zealand and trial activity continues across all alert levels
  • Details for Optimal Clinical Trials' activities are below

After 102 days of being COVID-19 free, New Zealand has a new outbreak. As at 9am Saturday 15th August 2020 we have 56 active cases, 17 of which are due to the new outbreak and the rest are imported cases. All are in managed isolation. Since the beginning of the pandemic New Zealand has had 1609 total confirmed and probable cases with 1531 recovered and 22 deaths1.

The New Zealand government has responded swiftly and as of Wednesday 12 August 12 noon Auckland has been moved to Alert level 3. The rest of New Zealand is at alert level 2. This will stay in place until 11:59pm Wednesday 26 August.  The Government aims to keep the economy going while prioritising peoples health.

Whilst this is regrettable we have been planning for this and have swung our plans into action. We continue to prioritise safety but also to continue operations and keep your studies moving.

Optimal Clinical Trials is considered an essential business by the New Zealand Government and so can continue to operate at all alert levels.

Below is a table detailing operations at each alert level. Our team will be in touch with you to keep things moving for existing studies and studies in start up. We will continue to communicate with you.

Please stay safe and we look forward to continuing to work with you.

Dr Barney Montgomery
Managing Director
Optimal Clinical Trials

1source: https://covid19.govt.nz

Further Information

Clinical Trial Landscape

Clinical Trials is considered an essential business in New Zealand and trial activity continues across all alert levels. Optimal and many other sites are set up to conduct trials with in clinic visits as well as virtual trials.

Ethics & Regulatory approval
New Zealand’s online application and approval system is fully operational, with approval times within 35 days. An expedited process has been implemented to approve COVID-19 research much more quickly.

Monitoring & Start up activities
Monitoring and start up activities continue – with New Zealand offering both on site remote support.

Local laboratories & imaging facilities
Private laboratories and radiology providers continue to support clinical trial activities.

Transportation & logistics
New Zealand borders remain open to freight, ensuring that IP supplies reach sites, and central laboratory specimens are delivered to overseas laboratories. Local couriers and transportation services remain operational at ground level, ensuring timely delivery of temperature sensitive supplies, dry ice etc.

 Recruitment & participant visits
Under all alert levels essential safety visits continue.

Brief information about New Zealand and Optimal Clinical Trials

  • NZ is part of Asia-Pacific: The world’s fastest growing clinical trials region.
  • Low rates of COVID-19 infection.
  • Fast and straight forward regulatory and streamlined ethics system- reducing start up time.
  • No IND required
  • High quality medical care
  • Politically stable
  • Population 4.8 million. Auckland is the largest city with population of 1.5 million.
  • Compliant with safety measures regarding COVID-19

We are keeping clinical trials running

Please contact us for more information about conducting you research in New Zealand. Or, click here to get your free guide: "Successful Clinical Trials: How to accelerate your clinical program; get your first patient in quickly and meet your clinical trial milestones"

New Zealand wants to help

Dr Barney Montgomery
Managing Director
barney@optimalclinicaltrials.com    ||    +64 21 951 954

Dr Liz Smaill
General Manager
liz@optimalclinicaltrials.com    ||    +64 21 538 865

Optimal Clinical Trials
P O Box 47476, Ponsonby, Auckland 1144
2nd Floor, 97 Grafton Rd, Grafton, Auckland 1010, New Zealand
P +64 (9) 303 4987 | F +64 (9) 379 6582

About Optimal Clinical Trials

Optimal Clinical Trials: We are people on a mission – to reduce suffering and help people around the world gain a better quality of life through research.
We are a private, independently owned clinical research site in Auckland (population 1.5m), New Zealand’s largest city. We have grown rapidly and won multiple awards.
We specialise in conducting commercial phase 1b to 3 non-oncology trials. We have a wide range of therapeutic areas with our expert investigators and specialists.
We regularly work with the world’s largest pharmaceutical companies, CRO’s and many biotech’s. We are known for our speed, quality and responsiveness to client’s needs.
The safety of our patients, staff and partners is our primary concern and we continue to maintain our extensive safety measures to minimise possible transmission.

Other News

Innovative Strategies For Successful Drug Development

We are living in an extraordinary time of scientific innovation, where our understanding of biology is exploding and our ability to improve human health is unprecedented with new opportunities to develop new innovative medicines and devices.

Read more
ANZ Region Rescues Stalled Global Clinical Trials

Randomized, controlled trials are considered the gold standard for evaluating the safety and efficacy of potential new medicines and therapies, as they provide a rigorous and unbiased way to compare treatments to placebo or standard care.

Read more
Global Pharma can accelerate commercial sales and registration in China through Real World Data

Hainan Boao Lecheng special zone is the first area in China where RWD can be widely used. The Lecheng Real World Study (RWS) pathway allows overseas drugs, medical devices, and IVDs with clinical urgency status, that have not been approved by the China NMPA, to be sold and used in real world clinical settings in the Hainan province, China.

Read more